Afig BERDELİ, Mustafa Serdar KALEMCİ, Fuat KIZILAY, Oktay NAZLI, Burak TURNA, Adnan ŞİMŞİR

The place of androgen receptor gene mutation analysis in the molecular diagnosis of prostate cancer and genotype phenotype relationship

Aim: To determine the relationship between androgen receptor (AR) gene polymorphism and prostate cancer in our society. Materials and methods: Thirty-nine patients diagnosed with prostate cancer and 34 benign prostatic hyperplasia (BPH) patients who were diagnosed in 2010 met the study criteria. The inclusion criteria included patients whose diagnosis was confirmed with a biopsy, with the presence of adequate pathologic material for review, between the ages of 40 and 80, and who were healthy men without a family history of prostate cancer. The exclusion criteria excluded men diagnosed with another cancer and those who had kin with a history of prostate cancer. A direct DNA sequencing method was utilized for detection of polymorphisms. Results: CAG repeat length varied from 13 to 28 (mean: 21.67) for the BPH group and 12 to 28 (mean: 21.74) for the prostate cancer group. Prostate-specific antigen (PSA) density and the androgen receptor (AR) CAG repeat had a statistically significant negative correlation in the BPH group. A statistically significant difference was associated between AR CAG repeat and PSA density. Conclusion: Randomized prospective studies should be planned with larger patient and control groups and with more variables, which may open new horizons in prostate cancer screening and early detection.

PDF

___

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics. CA Cancer J Clin 2005; 55: 74108.
2. Esen T. Türk Üroloji Yeterlilik Kurulları 3. Üroloji Yeterlilik Sınavına Hazırlık Kursu. Ders Notları Kitabı. 1. Baskı. İstanbul, Turkey: Türk Üroloji Derneği; 2006 (in Turkish).
3. Kantoff P, Giovannucci E, Brown M. The androgen receptor CAG repeat polymorphism and its relationship to prostate cancer. Biochim Biophys Acta 1998; 1378: 15.
4. Knoke I, Allera A, Wieacker P. Significance of the CAG repeat length in the androgen receptor gene (AR) for the transactivation function of an M780I mutant AR. Hum Genet 1999; 104: 257261.
5. Giovannucci E, Stampfer MJ, Krithivas K, Brown M, Dahl D, Brufsky A, Talcott J, Hennekens CH, Kantoff PW. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci USA 1997; 94: 3320 3323.
6. Stanford JL, Just JJ, Gibbs M, Wicklund KG, Neal CL, Blumenstein BA, Ostrander EA. Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk. Cancer Res 1997; 57: 11941198.
7. Sartor O, Zheng Q, Eastham JA. Androgen receptor gene CAG repeat length varies in a race-specific fashion in men without prostate cancer. Urology 1999; 53: 378380.
8. Kazemi-Esfarjani P, Trifiro MA, Pinsky L. Evidence for a repressive function of the long polyglutamine tract in the human androgen receptor: possible pathogenic relevance for the (CAG)n -expanded neuropathies. Hum Mol Genet 1995; 4: 523527.
9. Edwards A, Hammond HA, Jin L, Caskey CT, Chakraborty R. Genetic variation at five trimeric and tetrameric tandem repeat loci in four human population groups. Genomics 1992; 12: 241253.
10. Platz EA, Rimm EB, Willett WC, Kantoff PW, Giovannucci E. Racial variation in prostate cancer incidence and in hormonal system markers among male health professionals. J Natl Cancer Inst 2000; 92: 20092017.
11. Bratt O, Borg A, Kristoffersson U, Lundgren R, Zhang QX, Olsson H. CAG repeat length in the androgen receptor gene is related to age at diagnosis of prostate cancer and response to endocrine therapy, but not to prostate cancer risk. Br J Cancer 1999; 81: 672676.
12. Eeles RA, Edwards SM, Minter R. Androgen receptor polymorphisms: their association with prostate cancer risk, relapse and overall survival. Programs and abstracts of the 1998 Annual Meeting of the American Society of Human Genetics. Am J Hum Genet 1998; 4: A21.
13. Chamberlain NC, Driver ED, Mielsfeld RL. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucl Acid Res 1994; 22: 31813186.
14. Kufe DW, Pollack RE, Weichselbaum RR, Bast RC, Gansler TS, Holland JF, Frei E, editors. Cancer Medicine. 6th ed. Hamilton, ON, Canada: B.C. Decker; 2003..
15. Sawaya ME, Shalita AR. Androgen receptor polymorphisms (CAG repeat lengths) in androgenetic alopecia, hirsutism, and acne. J Cutan Med Surg 1998; 3: 915.
16. Balic I, Graham ST, Troyer DA, Higgins BA, Pollock BH, Johnson-Pais TL, Thompson IM, Leach RJ. Androgen receptor length polymorphism associated with prostate cancer risk in Hispanic men. J Urol 2002: 168: 22452248.
17. Mononen N, Ikonen T, Autio V, Rökman A, Matikainen MP, Tammela TL, Kallioniemi OP, Koivisto PA, Schleutker J. Androgen receptor CAG polymorphism and prostate cancer risk. Hum Genet 2002; 111: 166171.
18. Coughlin SS, Hall IJ. A review of genetic polymorphisms and prostate cancer risk. Ann Epidemiol 2002; 12: 182196.
19. Nelson KA, Witte JS. Androgen receptor CAG repeats and prostate cancer. Am J Epidemiol 2002; 155: 883890.
20. Lai CL, LEplattenier H, van den Ham R, Verseijden F, Jagtenberg A, Mol JA, Teske E. Androgen receptor CAG repeat polymorphisms in canine prostate cancer. J Vet Intern Med 2008; 22: 13801384.
21. Latil AG, Azzouzi R, Cancel GS, Guillaume EC, CochanPriollet B, Berthon PL, Cussenot O. Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways. Cancer 2001; 92: 11301137.
22. Bousema JT, Bussemakers MJ, van Houwelingen KP, Debruyne FM, Verbeek AL, de La Rosette JJ. Polymorphisms in the vitamin D receptor gene and the androgen receptor gene and the risk of benign prostatic hyperplasia. Eur Urol 2000; 37: 234238.
23. Salinas CA, Austin MA, Ostrander EO, Stanford JL. Polymorphisms in the androgen receptor and the prostatespecific antigen genes and prostate cancer risk. Prostate 2005; 65: 5865.
24. Jesser C, Mucci L, Farmer D, Moon C, Li H, Gaziano JM. Effects of G/A polymorphism, rs266882, in the androgen response element 1 of the PSA gene on prostate cancer risk, survival and circulating PSA levels. Br J Cancer 2008; 99: 17431747.